Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.73 |
| ▸ | MIF | P14174 | 1/20 | 0.73 |
| ▸ | PPARG | P37231 | 1/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | CNR1 | P21554 | 4/20 | 0.57 |
| ▸ | FAAH | O00519 | 3/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.57 |
| ▸ | CNR2 | P34972 | 2/20 | 0.57 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.57 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16661496 | 1.00 | ALDH1A1 (0.73) | ALDH1A1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL16659173 | 0.94 | MAPT (0.76) | ALDH1A1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL20795025 | 0.90 | MAPT (0.69) | ALDH1A1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL20795024 | 0.89 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL22902324 | 0.85 | MAPT (0.77) | ALDH1A1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL14379041 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL13931843 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL15159481 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL22902392 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL21067853 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4265257-A1 | COMBINATION OF A J-SERIES PROSTAGLANDIN-ETHANOLAMIDE AND A CHECKPOINT INHIBITOR FOR USE IN TREATING CANCER | East Carolina University (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3675866-B1 | EX VIVO METHODS FOR ACTIVATING IMMUNE CELLS | UNIV EAST CAROLINA (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11571401-B2 | Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response | EAST CAROLINA UNIVERSITY (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210177864-A1 | J-SERIES PROSTAGLANDIN-ETHANOLAMIDES AS NOVEL THERAPEUTICS FOR SKIN AND/OR ORAL DISORDERS | UNIV EAST CAROLINA (US) | 2021-06-17 | — | — | US | disclosed |
| US-10960013-B2 | J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders | EAST CAROLINA UNIVERSITY (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200306212-A1 | COMPOUNDS, COMPOSITIONS, KITS, AND METHODS FOR ACTIVATING IMMUNE CELLS AND/OR AN IMMUNE SYSTEM RESPONSE | EAST CAROLINA UNIVERSITY | 2020-10-01 | — | — | US | disclosed |
| US-20190091238-A1 | J-SERIES PROSTAGLANDIN-ETHANOLAMIDES AS NOVEL THERAPEUTICS FOR SKIN AND/OR ORAL DISORDERS | EAST CAROLINA UNIVERSITY | 2019-03-28 | — | — | US | disclosed |
| WO-2019046556-A1 | COMPOUNDS, COMPOSITIONS, KITS, AND METHODS FOR ACTIVATING IMMUNE CELLS AND/OR AN IMMUNE SYSTEM RESPONSE | EAST CAROLINA UNIVERSITY (US) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306212-A1 | COMPOUNDS, COMPOSITIONS, KITS, AND METHODS FOR ACTIVATING IMMUNE CELLS AND/OR AN IMMUNE SYSTEM RESPONSE | MYD88, NFATC1, CCR1 | ALDH1A1 1537/4885MEN1 2144/4885KMT2A 3016/4885 |
| US-11571401-B2 | Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response | MYD88, NFATC1, CCR1 | ALDH1A1 1537/4885MEN1 2144/4885KMT2A 3016/4885 |
| US-10960013-B2 | J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders | PTGES, PTGES2, HPGDS | ALDH1A1 237/4885MEN1 3518/4885KMT2A 2876/4885 |
| US-20210177864-A1 | J-SERIES PROSTAGLANDIN-ETHANOLAMIDES AS NOVEL THERAPEUTICS FOR SKIN AND/OR ORAL DISORDERS | PTGES, PTGES2, HPGDS | ALDH1A1 219/4885MEN1 3569/4885KMT2A 2916/4885 |
| US-20190091238-A1 | J-SERIES PROSTAGLANDIN-ETHANOLAMIDES AS NOVEL THERAPEUTICS FOR SKIN AND/OR ORAL DISORDERS | PTGES, PTGES2, HPGDS | ALDH1A1 237/4885MEN1 3518/4885KMT2A 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.